SCHEMBL7349348

SCHEMBL7349348

CCC(=O)c1cc2ccccc2oc1=O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.78
MAOB P27338 7/20 0.69
KDM4E B2RXH2 5/20 0.69
CA12 O43570 4/20 0.69
CA9 Q16790 4/20 0.69
CYP1A2 P05177 3/20 0.69
NT5E P21589 1/20 0.69
CA1 P00915 1/20 0.66
CA3 P07451 1/20 0.66
TSHR P16473 1/20 0.66
CA4 P22748 1/20 0.66
CA6 P23280 1/20 0.66
CA5A P35218 1/20 0.66
CA7 P43166 1/20 0.66
GPR35 Q9HC97 1/20 0.66
CA14 Q9ULX7 1/20 0.66
CA5B Q9Y2D0 1/20 0.66
ALDH1A1 P00352 6/20 0.63
HPGD P15428 4/20 0.63
MEN1 O00255 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13561369 0.88 LMNA (1.00) LMNAMAOBKDM4ECA12CA9
3-(2-Bromoacetyl)-Coumarin SCHEMBL28678576 0.85 LMNA (0.70) LMNAMAOBKDM4ECA12CA9
SCHEMBL26656965 0.84 LMNA (0.68) LMNAMAOBKDM4ECA12CA9
SCHEMBL15842724 0.84 LMNA (0.68) LMNAMAOBKDM4ECA12CA9
3-(2-Bromoacetyl)-Coumarin SCHEMBL30633043 0.84 LMNA (0.68) LMNAMAOBKDM4ECA12CA9
3-(2-Bromoacetyl)-Coumarin SCHEMBL3022073 0.84 LMNA (0.68) LMNAMAOBKDM4ECA12CA9
SCHEMBL29961413 0.84 LMNA (0.68) LMNAMAOBKDM4ECA12CA9
SCHEMBL13560755 0.83 LMNA (0.68) LMNAMAOBKDM4ECA12CA9
3-(2-Bromoacetyl)-Coumarin SCHEMBL28782184 0.83 KDM4E (0.68) LMNAMAOBKDM4ECA12CA9
SCHEMBL13561380 0.83 LMNA (0.67) LMNAMAOBKDM4ECA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160223558-A1 ANALYTE DETECTION USING NEAR-INFRARED FLUOROPHORES PORTLAND STATE UNIVERSITY (US) 2016-08-04 US disclosed
US-8927727-B2 Thiol detection THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) 2015-01-06 US disclosed
US-20120115128-A1 SELECTIVE PROTEIN LABELING THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (IL) 2012-05-10 US disclosed
US-20120115128-A1 SELECTIVE PROTEIN LABELING THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (IL) 2012-05-10 US disclosed
WO-2011082354-A2 THIOL DETECTION THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) 2011-07-07 WO disclosed
WO-2010129929-A1 SELECTIVE PROTEIN LABELING THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2010-11-11 WO disclosed
US-7700765-B2 DNA minor groove binding compounds UNIVERSITY OF STRATHCLYDE (GB) 2010-04-20 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
EP-0668860-B1 PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES UPJOHN CO (US) 2002-09-11 EP disclosed
EP-1203770-A1 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases PHARMACIA & UPJOHN COMPANY (US) 2002-05-08 EP disclosed
EP-0682663-B1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS UPJOHN CO (US) 2001-04-18 EP disclosed
US-6169181-B1 HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS PHARMACIA & UPJOHN COMPANY 2001-01-02 US disclosed
US-5852195-A Pyranone compounds useful to treat retroviral infections PHARMACIA & UPJOHN COMPANY (US) 1998-12-22 US disclosed
US-5686486-A 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections PHARMACIA & UPJOHN COMPANY (US) 1997-11-11 US disclosed
EP-0758327-A1 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1997-02-19 EP disclosed
EP-0682663-A1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-22 EP disclosed
WO-1995030670-A2 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-16 WO disclosed
EP-0668860-A1 PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES PHARMACIA & UPJOHN COMPANY (US) 1995-08-30 EP disclosed
WO-1994018188-A1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS THE UPJOHN COMPANY (US) 1994-08-18 WO disclosed
WO-1994011361-A1 PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES THE UPJOHN COMPANY (US) 1994-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160223558-A1 ANALYTE DETECTION USING NEAR-INFRARED FLUOROPHORES BLVRB, CBR3, AKR7A2 LMNA 2907/4885MAOB 338/4885KDM4E 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.